综述主要介绍了Mast、Dendritic、Monocyte、Macrophage、Neutrophils细胞，其中Neutrophils不是很详细，因此只总结了前4中细胞的亚群marker和特征。以思维导图形式总结在幕布，方便以后增删改查。
幕布文档链接: https://www.mubucm.com/doc/7V2nk7N6B_1 密码: 9adx
Mast
marker: TPSAB1, CPA3, KIT, MS4A2
high proportion in cancer than normal tissue;
down-regulate the expression of TNF;
在不同癌症中其量与预后有正反关系;
高表达VEGFA促进血管新生
表达IL10,TGFB, 招募Treg促进免疫抑制
高表达PD-L1
释放CCL3、CCL5招募T和NK
Dendritic
Conventional DC (cDC)
cDC1
marker: XCR1, CLEC9A, BATF3, IRF8
mainly antitumor
cDC2
marker: CLEC10A, FCER1A, CD1C, CD1E
促进Th2、抑制Th17、与CD4+ T互作促进肿瘤
activates antitumor CD4+ conventional T cells (Tconvs) in the absence of Treg
Plasmacytoid DC (pDC)
marker: MZB1, LILRA4, IRF7, IL3RA
immunosuppressive；
anti-tumor: release IFNα/β & TNFα
LAMP3+ DC (mregDC)
marker: LAMP3, BIRC3, CCR7, FSCN1
high expression of LAMP3, immune regulators [CD274 & FAS], maturation genes (CD40 & CD80) and migratory genes (CCR7 & FSCN1)
2.enriched in intratumor & invasive margin tumor tissues;
originate: cDC1 and cDC2,;
high expression of CCL17, CCL19 & CCL22;
suppress CD8+ T cells self-renew and function through PD-L1/PD-1 pathway;
interact with CD8+ T cells from cDC1 ;
interact with Tregs from cDC2;recuit Treg;
C3
marker: CD88−CD1c+CD163+
pro-inflammatory: trigger the expansion of tissue-resident memory CD8+ T cells and enhance MHC expression
intermediated functional subtype between cDC2 and monocyte, produces TNFα as monocyte & IL23, IL12p70 as cDC2
Monocyte
Classical monocyte
marker: FCN1, CD14, S100A8, VCAN
Nonclassical monocyte
marker: FCN1, FCGR3A, LILRB2, LST1
Intermediate monocyte
marker: FCN1, CD14, FCGR3A
Macrophage
classically activated macrophages (M1)
由Toll样受体配体[如脂多糖和干扰素-γ]诱导)
表达促炎细胞因子和诱导型一氧化氮合酶
增强抗肿瘤 Th1 反应并拮抗调节性免疫细胞的抑制活性
alternatively activated macrophages (M2)
由IL-4或IL-13诱导
表达精氨酸酶1、CD206、CD163、IL-4R、TGF-β1和血小板衍生生长因子(PDGF)
促进血管生成、肿瘤生长和转移
Monocyte-like macrophages
marker: FCN1, CD163, CD68
FOLR2+ TRM
marker: FOLR2, MRC1
enrich: tumor stroma
prime effector CD8+ T cells
beneficial to survival
TREM+ recruited macrophages
enrichment and activation of T cells and nature killer (NK) cells, which furtherly enhanced ICB therapy
MDSCs-like macrophages
marker: MARCO & TREM1
Myeloid-derived suppressor cells
TAM-like macrophage
marker: CD169, CX3CR1, TREM2
immature macrophage;
Enriched in TME with T cells infiltrated or excluded
LYVE1+ TRM
marker: LYVE1, C1QC, PLTP, SEPP1
locate: adjacent to blood vessels
NLRP3+ TRM
marker: NLRP3, IL1B, CXCL2, EREG
promote the inflammatory response
Alveolar TRM
marker: PPARG, MARCO, MRC1, MSR1
canonical TRM
ISG15+ TAM
marker: ISG15, CXCL10, IFITM3, GBP1
C1QC+ TAM
marker: C10A, C1QB, C1QG, APOE
phagocytosis and antigen presentation
originate: FCN1+ monocytes
locate: adjacent zones
SPP1+ TAM
marker: SPP1, VEGFA, GPNMB, FN1
angiogenesis;
worse prognosis;
associate with ICB drug resistance
interact with tumor-specific FAP+ fibroblasts to promote tumor progression
SPP1+ macrophages and TREM2+ macrophages might largely be overlapped with each other
网友评论